Comparative Pharmacology
Head-to-head clinical analysis: TEPYLUTE versus URACIL MUSTARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEPYLUTE versus URACIL MUSTARD.
TEPYLUTE vs URACIL MUSTARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
Uracil mustard is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
100 mg orally once daily
1 mg orally daily for 3 weeks, then 1 mg daily every 4 weeks, or 0.15 mg/kg orally once weekly.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Clinical Note
moderateUracil mustard + Digoxin
"Uracil mustard may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateUracil mustard + Digitoxin
"Uracil mustard may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateUracil mustard + Deslanoside
"Uracil mustard may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateUracil mustard + Acetyldigitoxin
"Uracil mustard may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 6–8 hours in patients with normal renal function; may be prolonged with renal impairment
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Primarily renal (56-80% as unchanged drug and metabolites); minor fecal (10%)
Category C
Category C
Alkylating Agent
Alkylating Agent